David Kirk

The Hadean Platform, a distributed computing platform, streamlines running applications via cloud by removing excessive middleware and helping scale the process – a journey that has taken them from the world of gaming to the modeling a pandemic.
Synthetic biology – an engineering approach to biological science– is gaining traction in biotechnology worldwide.
“We are Earth’s Tech Support,” declared Randall Kirk, Executive Chairman of the Board of Directors and former CEO of Intrexon. His company is one of the biggest developers of synthetic biology (or engineering biology) applications in therapeutics, agriculture and chemicals.
Several trends have emerged in synthetic biology since the field developed nearly 20 years ago. In that time, some technologies have crystallized and developed into key trends that crop up time again within synthetic biology conversations.
A direct result of using better technology leads to an increase in high quality data gathered.
DNA is structurally suited to storing information for extended periods of time, given its half-life of 521 years.
The recent announcement of CRISPR Prime, a novel version of the system, addresses the targeting problem and brings CRISPR-based therapy one step closer to reality.
Carbon capture is becoming a major pillar in developing a sustainable bioeconomy, and companies want to partner with the major emitters of waste gas to turn their costly pollution into a valued product.
Because algae can grow simply on carbon dioxide and light, they are attractive to companies looking at generating protein from greenhouse gases.
Aleph Farms announced last week they 3D printed a small piece of muscle tissue on the International Space Station. The success of this miniature steak highlights the key advantage of cultivated meat: you can make it anywhere.
Enzymatic DNA synthesis may be a still some way off, however the route to overcoming the DNA synthesis bottleneck is clearer than ever.